Audit Information |
12 Months Ended |
|---|---|
Dec. 31, 2024 | |
| Auditor [Table] | |
| Auditor Name | Marcum llp |
| Auditor Firm ID | 688 |
| Auditor Location | Houston, Texas |
| Auditor Opinion [Text Block] |
Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Actinium Pharmaceuticals, Inc. (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, changes in stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2024 and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America. |